Pediatric chronic myelogenous leukemia(CML), a malignant hematopoietic stem cell disease driven by the BCR/ABL fusion gene. The emergence of tyrosine kinase inhibitor(TKI) has significantly improved long-term survival rates in children with CML, marking a milestone in its therapeutic history. However, TKI may exert long-term effects on pediatric growth and development, necessitating careful consideration of lifelong treatment tolerance and quality of life. The status of the second-generation TKI, dasatinib and nilotinib, in the first-line treatment of pediatric CML has been further clarified. The long-term value of imatinib has been precisely evaluated in specific populations. The novel agents like asciminib, which offer new avenues to overcome resistance. This review systematically summarized key recent progress in targeted therapy for pediatric CML, deeply analyzed the efficacy and safety profiles of each TKI generation,discussed individualized treatment selection strategies, and envisioned future directions guided by precision medicine and functional cure.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |